Neffy, a single-dose nasal spray administered into one nostril, is approved for use in adult and pediatric patients who weigh at least 30 kilograms.

“Some people, particularly children, may delay or avoid treatment due to fear of injections,” said Kelly Stone, an associate director at the FDA’s Center for Drug Evaluation and Research, adding that the availability of the nasal spray may reduce barriers to rapid treatment.